GlassScriptPhysician profile
Stefano A Bini
NPI 1619055415
$3,210,720.19
in general payments reported to CMS, 2019-2025
5 companies · $764K in 2025
The $764K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $371K · 2021: $548K · 2022: $582K · 2023: $662K · 2024: $214K · 2025: $764K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $814K · Consulting Fee: $734K · Education: $46K · Travel and Lodging: $41K · Food and Beverage: $5,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $813,824.67 |
| Consulting Fee | $733,915.84 |
| Education | $45,750.00 |
| Travel and Lodging | $40,899.55 |
| Food and Beverage | $5,733.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,409,230.72 | 2019-2024 | Accolade, Mako, Triathlon |
| Zimmer Biomet Holdings, INC. | $801,293.64 | 2022-2025 | Persona, G7, Arcos |
| Conformis, INC. | $144.08 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $36.04 | 2025 | |
| Ethicon US, LLC | $15.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefano Bini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.